Soo Min Jeon

Soo Min Jeon

Auto-generated profile, based on publicly available information

Soo Min Jeon

Jeju Research Institute of Pharmaceutical Science, College of Pharmacy, Jeju National University, Jeju, Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ISInmyung Song
Inmyung Song
JKJinwon Kwon
Jinwon Kwon
SJSoo Min Jeon
Soo Min Jeon
Happiness is predicted by social relationships in general and contact frequency in particular. This study aims to examine if the relative importance of social contacts with the closest family/relative, friend, and neighbor in happiness changes with advancing age. We used data for all participants aged 19 years and older (n = 229,099) in the 2019 Community Health Survey, which measured the frequency of contact with the closest relative/family, neighbor, and friend among a representative sample of Koreans between August 16 and October 31, 2019. The Shapley value decomposition method was used to measure the relative importance of each predictor of happiness. Overall, contact frequency was positively associated with happiness (p<0.001). The relative importance value of contact with the closest family, neighbor, and friend to happiness increased from 4.70%, 3.98%, and 7.35%, respectively, in the 19–29 years group to 8.09%, 4.44%, and 11.00%, respectively, in the 60 years and older group. Frequent interactions with the closest friend could have a greater impact on happiness in old age than those with the closest family and neighbor.

30 January 2024 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
SJSoo Min Jeon
Soo Min Jeon
HLHyunJoo Lim
HyunJoo Lim
HCHyo-Bin Cheon
Hyo-Bin Cheon
JRJuhee Ryu
Juhee Ryu
JKJinwon Kwon
Jinwon Kwon
Background: Drug-induced suicide (DIS) is a severe adverse drug reaction (ADR). Although clinical trials have provided evidence on DIS, limited investigations have been performed on rare ADRs, such as suicide. Objective: We aimed to systematically review case reports on DIS to provide evidence-based drug information. Methods: We searched PubMed to obtain case reports regarding DIS published until July 2021. Cases resulting from drugs that are no longer used or are nonapproved, substance use, and suicidal intentions were excluded. The quality of each case report was assessed using the CASE (Case Reports) checklist. We extracted data regarding demographics, medication history, suicide symptoms, and symptom improvement and evaluated the causality of DIS using the Naranjo score. Furthermore, to identify the potential suicidal risk of the unknown drugs, we compared the results of the causality assessment with those of the approved drug labels. Results: In 83 articles, we identified 152 cases involving 61 drugs. Antidepressants were reported as the most frequent causative drugs of DIS followed by immunostimulants. The causality assessment revealed 61 cases having possible, 89 cases having probable, and 2 cases having definite relationships with DIS. For approximately 85% of suspected drugs, the risk of suicidal ADRs was indicated on the approved label; however, the approved labels for 9 drugs, including lumacaftor/ivacaftor, doxycycline, clozapine, dextromethorphan, adalimumab, infliximab, piroxicam, paclitaxel, and formoterol, did not provide information about these risks. Conclusions: We found several case reports involving drugs without suicide risk information on the drug label. Our findings might provide valuable insights into drugs that may cause suicidal ADRs.

13 April 2022 in Evidence Based Mental Health
Verified
Journal Article
Open access
PDF file
SJSoo Min Jeon
Soo Min Jeon
JCJaehyeong Cho
Jaehyeong Cho
DLDong Yun Lee
Dong Yun Lee
JKJinwon Kwon
Jinwon Kwon
Objective There is little evidence for finding optimal antipsychotic treatment for schizophrenia, especially in paediatrics. To evaluate the performance and clinical benefit of several prediction methods for 1-year treatment continuation of antipsychotics. Design and Settings Population-based prognostic study conducting using the nationwide claims database in Korea. Participants 5109 patients aged 2–18 years who initiated antipsychotic treatment with risperidone/aripiprazole for schizophrenia between 2010 and 2017 were identified. Main outcome measures We used the conventional logistic regression (LR) and common six machine-learning methods (least absolute shrinkage and selection operator, ridge, elstic net, randomforest, gradient boosting machine, and superlearner) to derive predictive models for treatment continuation of antipsychotics. The performance of models was assessed using the Brier score (BS), area under the receiver operating characteristic curve (AUROC) and area under the precision-recall curve (AUPRC). The clinical benefit of applying these models was also evaluated by comparing the treatment continuation rate between patients who received the recommended medication by models and patients who did not. Results The gradient boosting machine showed the best performance in predicting treatment continuation for risperidone (BS, 0.121; AUROC, 0.686; AUPRC, 0.269). Among aripiprazole models, GBM for BS (0.114), SuperLearner for AUROC (0.688) and random forest for AUPRC (0.317) showed the best performance. Although LR showed lower performance than machine learnings, the difference was negligible. Patients who received recommended medication by these models showed a 1.2–1.5 times higher treatment continuation rate than those who did not. Conclusions All prediction models showed similar performance in predicting the treatment continuation of antipsychotics. Application of prediction models might be helpful for evidence-based decision-making in antipsychotic treatment.

8 March 2023 in Journal of Medical Internet Research
Verified
Journal Article
Open access
KKKarina Karapetian
Karina Karapetian
SJSoo Min Jeon
Soo Min Jeon
JKJinwon Kwon
Jinwon Kwon
YSYoung-Kyoon Suh
Young-Kyoon Suh
Background: Drug-induced suicide has been debated as a crucial issue in both clinical and public health research. Published research articles contain valuable data on the drugs associated with suicidal adverse events. An automated process that extracts such information and rapidly detects drugs related to suicide risk is essential but has not been well established. Moreover, few data sets are available for training and validating classification models on drug-induced suicide. Objective: This study aimed to build a corpus of drug-suicide relations containing annotated entities for drugs, suicidal adverse events, and their relations. To confirm the effectiveness of the drug-suicide relation corpus, we evaluated the performance of a relation classification model using the corpus in conjunction with various embeddings. Methods: We collected the abstracts and titles of research articles associated with drugs and suicide from PubMed and manually annotated them along with their relations at the sentence level (adverse drug events, treatment, suicide means, or miscellaneous). To reduce the manual annotation effort, we preliminarily selected sentences with a pretrained zero-shot classifier or sentences containing only drug and suicide keywords. We trained a relation classification model using various Bidirectional Encoder Representations from Transformer embeddings with the proposed corpus. We then compared the performances of the model with different Bidirectional Encoder Representations from Transformer–based embeddings and selected the most suitable embedding for our corpus. Results: Our corpus comprised 11,894 sentences extracted from the titles and abstracts of the PubMed research articles. Each sentence was annotated with drug and suicide entities and the relationship between these 2 entities (adverse drug events, treatment, means, and miscellaneous). All of the tested relation classification models that were fine-tuned on the corpus accurately detected sentences of suicidal adverse events regardless of their pretrained type and data set properties. Conclusions: To our knowledge, this is the first and most extensive corpus of drug-suicide relations.

11 April 2023 in European Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
PDF file
SJSoo Min Jeon
Soo Min Jeon
YLYu Jin Lee
Yu Jin Lee
JKJinwon Kwon
Jinwon Kwon

17 November 2025 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
DLDong Yun Lee
Dong Yun Lee
SCSangHun Cha
SangHun Cha
JKJin-Won Kwon
Jin-Won Kwon
RPRae-Wong Park
Rae-Wong Park
SJSoo Min Jeon
Soo Min Jeon
This study aimed to evaluate the persistence and treatment modification patterns of three commonly used selective serotonin reuptake inhibitors (SSRIs)—fluoxetine, escitalopram, and sertraline—in children and adolescents with depression. We conducted a nationwide population-based retrospective cohort study using the Health Insurance Review and Assessment Service database of South Korea (2007–2019). Patients aged 5–19 years who were newly prescribed one of three SSRIs between 2009 and 2018 were included. During a one-year follow-up period, we assessed treatment persistence and categorized treatment changes as simple discontinuation, switching, combination with another antidepressant, and augmentation with antipsychotics. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated via Cox proportional hazards models. Only approximately 3% of patients remained on their initial SSRIs after one year, with most treatment changes occurring due to simple discontinuation, followed by switching, augmentation, and combination. Fluoxetine was associated with the lowest risk of treatment modification, particularly for combination and augmentation. The lowest switching rates were associated with escitalopram, whereas the lowest risk of simple discontinuation was associated with sertraline. Sociodemographic and clinical factors, including psychiatric comorbidities, significantly influence treatment patterns. Each SSRI exhibited distinct patterns of treatment modifications, with no single agent consistently outperforming the other agents. These findings highlight the need for individualized SSRI selection that considers both pharmacological profiles and patient characteristics in the real-world management of pediatric depression. Not applicable.